BeOne Medicines (BEIGF) Share-based Compensation (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Share-based Compensation data on file, last reported at $123.4 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $123.4 million, up 29.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $538.7 million (up 20.14% YoY), and the FY2025 annual result was $510.9 million, up 15.68% from the prior year.
• Share-based Compensation was little changed at $123.4 million in Q1 2026 per BEIGF's latest filing, from $123.8 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $150.8 million in Q2 2025 and troughed at $65.6 million in Q1 2022.
• A 5-year average of $102.7 million and a median of $96.0 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 43.03% in 2022, then climbed 7.68% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $78.1 million in 2022, then rose by 18.94% to $92.9 million in 2023, then increased by 15.82% to $107.6 million in 2024, then gained by 15.0% to $123.8 million in 2025, then dropped by 0.33% to $123.4 million in 2026.
• Business Quant data shows BEIGF's Share-based Compensation at $123.4 million in Q1 2026, $123.8 million in Q4 2025, and $140.8 million in Q3 2025.